Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Òåðàïèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 30.01.2007, 09:32
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Áîëüøîå ñïàñèáî çà èíôîðìàöèþ î òîì, ÷òî êíèæêè ïðîäàþòñÿ íà àìàçîíå - íèêîãäà áû ñàì íå äîãàäàëñÿ.
Áûëî áû åùå áîëåå ïðèÿòíî ïîëó÷èòü îò Âàñ îòâåò íà âîïðîñ, ãäå Âû âñòðå÷àëè èíîå îòíîøåíèå ê îáñóæäàåìûì ïðîäóêòàì, íåæåëè ïðèçíàíèå èõ ÁÀÄàìè?
Íå çíàþ, ÷òî çàñòàâèëî Âàñ ïîñ÷èòàòü íåóâàæàåìûì èññëåäîâàíèå, ïðèâåäåííîå â NEJM, êñòàòè, ïðèçâàííîå èçíà÷àëüíî ïîääåðæàòü Âàøó òî÷êó çðåíèÿ (íåóæåëè Âàì íå ïîíðàâèëèñü âûâîäû â äàííîì òðàéëå è îòçûâû â ñòàòüÿõ ïî òåìå âíèçó òåêñòà?).
Öèòàòà:
Ñîîáùåíèå îò Dr.
P.S. Íàñ÷åò òîãî, êòî è ÷òî ñîäåðæèò, â ðîññèéñêèõ øêîëàõ ïðåïîäàþò òàêîé çàêîí:
Çàêîí ïîñòîÿíñòâà ñîñòàâà âåùåñòâ - êàæäîå õèìè÷åñêè ÷èñòîå âåùåñòâî, ìîëåêóëÿðíîãî ñòðîåíèÿ, íåçàâèñèìî îò ìåñòà íàõîæäåíèÿ è ñïîñîáà ïîëó÷åíèÿ èìååò îäèí è òîò æå ïîñòîÿííûé ñîñòàâ.
À ê âûòÿæêàì èç õðÿùåé ýòî òîæå îòíîñèòñÿ?

 öåëîì ñèòóàöèþ ìîæíî îïèñàòü òàêèì çàèìñòâîâàíèåì:
Öèòàòà:
Oral glucosamine is commonly used for the treatment of osteoarthritis. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. Its use as a therapy for osteoarthritis appears safe, but there is conflicting evidence as to its effectiveness (Laverty et al., 2005; Biggee et al., 2005).
From a clinical perspective, the administration of glucosamine did not prevent fibrillation and/or erosions of the articular cartilage in all of the treated animals, and no effects were detected in the medial joint compartments. (Ýòî âûñêàçûâàíèå ïåðâîãî àâòîðà, ðàáîòàþùåãî íà æèâîòíûõ ìîäåëÿõ).
With an intensification of research in this field come new clinical and basic science data, sometimes with surprising results. These confirm the considerable potential for a role of nutritional interventions for osteoarthritis, but they emphasize the need for systematic scientific evaluation of the claims made for such products. (Èç ðå÷è âòîðîãî àâòîðà, èçó÷àþùåãî âëèÿíèå ïèùåâûõ äîáàâîê íà ëþäÿõ).

PS: Ê óíûíèþ, â èíîì àñïåêòå äàííûå âåùåñòâà íèêåì íå ðàññìàòðèâàþòñÿ óæå ñåìü ëåò (åñëè êîíå÷íî, íå ññûëàòüñÿ íà ðóìûíñêèå èñòî÷íèêè).
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 30.01.2007, 10:30
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,313
Ïîáëàãîäàðèëè 33,197 ðàç(à) çà 31,547 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè,

Ïîæàëóé, ñàìîå ñâåæåå (íîÿáðü 2006) ïî òåìå îòñþäà:

Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: Executive Summary From AHRQ

Agency for Healthcare Quality and Research (AHRQ)

Ôðàãìåíò âûâîäîâ (ïîëíûé òåêñò) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Glucosamine and chondroitin

In one large, good-quality trial the combination of pharmaceutical-grade glucosamine hydrochloride plus chondroitin (not currently available in the United States) was not superior to placebo among all patients studied. Neither glucosamine nor chondroitin alone was superior to placebo. In an analysis of a small subgroup of patients with at least moderate baseline pain, there was a modest benefit for pain relief, but this did not appear to be a preplanned analysis.

Systematic reviews of older trials found glucosamine modestly superior to oral NSAIDs and placebo in most trials, but there was some inconsistency between trials, most trials had some flaws and results may not be directly applicable to the United States because the positive trials primarily evaluated pharmaceutical-grade glucosamine available in Europe.

Only 2 of 20 placebo-controlled trials assessed effects of glucosamine on radiologic disease progression. One fair- and one good-quality trial found pharmaceutical-grade glucosamine superior to placebo for progression of knee joint space narrowing over 3 years.

Glucosamine and chondroitin were generally well tolerated and no serious adverse events were reported in clinical trials.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 30.01.2007, 16:42
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Áûëî áû åùå áîëåå ïðèÿòíî ïîëó÷èòü îò Âàñ îòâåò íà âîïðîñ, ãäå Âû âñòðå÷àëè èíîå îòíîøåíèå ê îáñóæäàåìûì ïðîäóêòàì, íåæåëè ïðèçíàíèå èõ ÁÀÄàìè?
Ñåé÷àñ ïîñìîòðèì, êòî ó íàñ çíà÷èòñÿ â ñïèñêå èçâåñòíûõ ÁÀÄîòîðãîâöåâ

Harrison's Principles of Internal Medicine 16th Edition

Several studies have shown glucosamine to be superior to placebo and comparable to NSAIDs37 with respect to efficacy in patients with knee OA, and to have a better safety profile than NSAIDs. However, the efficacy of neither glucosamine nor chondroitin sulfate has been examined in large, well-designed placebo-controlled trials. In a meta-analysis of randomized, double-blind, placebo-controlled studies of glucosamine and chondroitin sulfate, moderate symptomatic benefit was demonstrated for both agents, relative to placebo. In studies of chondroitin sulfate, symptomatic improvement was apparent as long as 12 months after the onset of treatment. However, when only high-quality or large-size trials were considered, the effect sizes for glucosamine and chondroitin sulfate were diminished, i.e., the better the study design, the smaller the therapeutic benefit. In three recent randomized, double-blind trials in which the manufacturer did not have access to the raw data and was not involved in data analysis, glucosamine was no more effective than placebo.

The question arises whether glucosamine is "chondroprotective." Results of two recent randomized clinical trials have led to the suggestion that glucosamine not only improves joint pain in patients with knee OA1, but protects against articular cartilage damage, based upon analyses of changes in joint space width in the standing anteroposterior (AP) knee radiograph. However, concern has been expressed about the interpretation of the results of these studies because of limitations of the radiographic methods employed. A multicenter study supported by the National Institutes of Health, the Glucosamine Chondroitin Arthritis Intervention Trial (GAIT), is in progress which is comparing glucosamine, chondroitin sulfate, the combination, and celecoxib with placebo in patients with knee OA. Although the primary outcome measure is joint pain after 6 months of treatment, approximately 50% of the subjects will be maintained on treatment for 2 years and radiographs obtained at baseline will be compared with those obtained after 1 year and 2 years of treatment.


Current Medical Diagnosis & Treatment 2007, Forty-Sixth Edition (öèòàòà âûøå)

Diagnosis and treatment of adult degenerative joint disease (DJD) of the knee.

GUIDELINE STATUS
This is the current release of the guideline.


The nutraceutical agents glucosamine (1500 mg qD) and chondroitin sulfate (1200 mg qD) are widely available and tried by patients. A systematic quality assessment and meta-analysis of double-blind, placebo-controlled trials that tested glucosamine or chondroitin for hip or knee osteoarthritis concluded that some degree of efficacy appears probable for these preparations. It is reasonable to recommend a 60-day trial of the combination of glucosamine and chondroitin sulfate, leaving the decision for ongoing (continuing) therapy to patients on an individual basis.

Âîò òóò ÿ è õî÷ó ñäåëàòü íåáîëüøîå ðåçþìå - ÁÀÄû, êàê èçâåñòíî, íè÷åãî ëå÷èòü è ïðîôèëàêòèðîâàòü ïðàâà íå èìåþò, ïîýòîìó ðàññìîòðåíèå èõ â êà÷åñòâå ËÅ×ÅÍÈß (î âåëèêîé ýôôåêòèâíîñòè ãîâîðèòü íå ïðèõîäèòñÿ, íî è ñîâñåì ðàâíÿòü ñ ïëàöåáî òîæå) ÁÀÄàìè äàííûå âåùåñòâà íå äåëàåò. Âî ìíîãèõ ñòðàíàõ çàðåãèñòðèðîâàíû êàê ëåêàðñòâà

Öèòàòà:
Ñîîáùåíèå îò Hard
Íå çíàþ, ÷òî çàñòàâèëî Âàñ ïîñ÷èòàòü íåóâàæàåìûì èññëåäîâàíèå, ïðèâåäåííîå â NEJM, êñòàòè, ïðèçâàííîå èçíà÷àëüíî ïîääåðæàòü Âàøó òî÷êó çðåíèÿ (íåóæåëè Âàì íå ïîíðàâèëèñü âûâîäû â äàííîì òðàéëå è îòçûâû â ñòàòüÿõ ïî òåìå âíèçó òåêñòà?).

ß ïðèâåë òî÷íóþ öèòàòó òîãî, ÷òî ìíå ïîêàçàëîñü íåóâàæàåìûì, ýòî áûëà ññûëêà íà ôîðóì. Èññëåäîâàíèå ìíå èçâåñòíî, ÿ åãî óâàæàþ

Öèòàòà:
Ñîîáùåíèå îò Hard
PS: Ê óíûíèþ, â èíîì àñïåêòå äàííûå âåùåñòâà íèêåì íå ðàññìàòðèâàþòñÿ óæå ñåìü ëåò (åñëè êîíå÷íî, íå ññûëàòüñÿ íà ðóìûíñêèå èñòî÷íèêè).
Ñåìü ëåò? Êàêàÿ äîñàäà! Íàäî áû íàïèñàòü ýòèì ëþäÿì:

Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher

Îíè íå â êóðñå
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 31.01.2007, 03:27
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Dr.
Îíè íå â êóðñå
Ìåæäó òåì, ïðèâåäåííûé Âàìè òåêñò óêàçûâàåò íà òî, ÷òî îíè òàêè â êóðñå:
Öèòàòà:
The nutraceutical agents glucosamine (1500 mg qD) and chondroitin sulfate (1200 mg qD) are widely available and tried by patients.
Îáðàòèòå, âíèìàíèå - òóò òàê è ñêàçàíî: "nutraceutical agents", ÷òî â ïåðåâîäå îçíà÷àåò "ïèùåâûå äîáàâêè", ò.å. "ÁÀÄû".
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 01.02.2007, 16:19
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Ìåæäó òåì, ïðèâåäåííûé Âàìè òåêñò óêàçûâàåò íà òî, ÷òî îíè òàêè â êóðñå:
Îáðàòèòå, âíèìàíèå - òóò òàê è ñêàçàíî: "nutraceutical agents", ÷òî â ïåðåâîäå îçíà÷àåò "ïèùåâûå äîáàâêè", ò.å. "ÁÀÄû".
Ïðèâåäåííûå ìíîé (è Âàìè) òåêñòû ñâèäåòåëüñòâóþò î òåðàïåâòè÷åñêîé ýôôåêòèâíîñòè. À ÁÀÄû ïî îïðåäåëåíèþ íå ìîãóò åé îáëàäàòü . Ïîýòîìó è ðàññìàòðèâàþòñÿ äàííûå âåùåñòâà â ðàçëè÷íûõ ðóêîâîäñòâàõ èñêëþ÷èòåëüíî â ðàçäåëå "ëå÷åíèå", à íèêàê íå â "âîñïîëíè â ñåáå äåôèöèò õðÿùåé, åñëè òû êóøàåøü ìàëî õîëîäöà"

Êîììåíòàðèè ê ñîîáùåíèþ:
vmark îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 02.02.2007, 07:05
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Post

Ñîâåðøåííî íàîáîðîò - ñâèäåòåëüñòâóþò îá îòñóòñòâèè äîêàçàòåëüñòâ ýôôåêòèâíîñòè - îáû÷íûå èñïûòàíèÿ áèîäîáàâîê ñ ýôåìåðíîé íàäåæäîé ïðîòîëêíóòü èõ â ðàçäåë ëåêàðñòâ.
À ïîñêîëüêó íèêàêîé ýôôåêòèâíîñòè â äåéñòâèè ãëþêîçàìèíîâ, õîíäðîèòèíîâ è ðîäñòâåííûõ èì âåùåñòâ äîêàçàíî íå áûëî, âñå ýòè âåùåñòâà, íåçàâèñèìî îò òîãî, íàçûâàþòñÿ îíè õîíäðîïðîòåêòîðàìè èëè ïðîñòî áèî-àêòèâíûìè àìèíîñàõàðàìè, ïðîèçâîäÿòñÿ èç êîðîâüèõ õðÿùåé èëè êðåâåòî÷íûõ õèòèíîâ, ïðîäàþòñÿ äëÿ ïîòðåáëåíèÿ áîëüíûìè ñ àðòðèòàìè èëè ïðîñòî "îò âñåõ áîëåçíåé", ÿâëÿþòñÿ "dietary supplements", "nutraceutical agents", "Alternative Medicine pills" è òîìó ïîäîáíûå ïóñòûøêè, âñåãäà îçíà÷àþùèå ÁÀÄû, òîëüêî ÁÀÄû è íè÷åãî, êðîìå ÁÀÄîâ (âíå ñâÿçè ñ òåì, ÷òî ïåðåïå÷àòûâàåòñÿ â Õàððèñîíå èç èçäàíèÿ â èçäàíèå íà ïðîòÿæåíèå äåñÿòêîâ ëåò).
Ìîæåò áûòü, áîëåå óáåäèòåëüíûì ñòàíåò [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].


[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Glucosamine and chondroitin sulfate are classified as a nutritional supplement - äàæå , êîãäà èìè êîðìÿò äîìàøíèõ ðó÷íûõ êðûñ ).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Ñì. "backgraund"; èç èñòîðèè: êîå-ãäå â Åâðîïå îíè ïîêà åùå îñòàþòñÿ òèïà ëåêàðñòâàìè...)
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 03.02.2007, 14:15
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Ñîâåðøåííî íàîáîðîò - ñâèäåòåëüñòâóþò îá îòñóòñòâèè äîêàçàòåëüñòâ ýôôåêòèâíîñòè - îáû÷íûå èñïûòàíèÿ áèîäîáàâîê ñ ýôåìåðíîé íàäåæäîé ïðîòîëêíóòü èõ â ðàçäåë ëåêàðñòâ.

Äà? Åñòü ïðåòåíçèè ê äèçàéíó? Ê æóðíàëàì, èõ îïóáëèêîâàâøèì? Ê àìåðèêàíñêèì ðóêîâîäñòâàì ïî ÎÀ?

Öèòàòà:
Ñîîáùåíèå îò Hard
À ïîñêîëüêó íèêàêîé ýôôåêòèâíîñòè â äåéñòâèè ãëþêîçàìèíîâ, õîíäðîèòèíîâ è ðîäñòâåííûõ èì âåùåñòâ äîêàçàíî íå áûëî
Ñòðîãî ãîâîðÿ, ýòî íå ñîâñåì òàê (ñ) Àëîí. Òî÷íåå, íàìåðåííîå âðàíüå

Äëÿ êîãî ÿ öèòèðîâàë:

See Related Guideline from CURRENT Practice Guidelines in Primary Care 2006

Analgesic and Anti-inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) (see Table 5–5) are more effective (and more toxic) than acetaminophen for osteoarthritis of the knee or hip. Their superiority is most convincing in those with severe disease. Patients with mild disease should start with acetaminophen (2.6–4 g/d). Glucosamine and chondroitin sulfate are also effective and safe for knee osteoarthritis; glucosamine may even reduce progression of knee osteoarthritis. NSAIDs should be considered for patients who do not respond to acetaminophen, chondroitin sulfate, and glucosamine. (See discussion of NSAID toxicity in the section on treatment of rheumatoid arthritis.) High doses of NSAIDs, as used in more inflammatory arthritides, are unnecessary.


Ïðàâäà, õîíäðîïðîòåêòîðû, ñóäÿ ïî âñåìó, êàê è âñå îñòàëüíûå ëåêàðñòâà íå çàìåäëÿþò ïðîãðåññèðîâàíèÿ ÎÀ. Òåì íå ìåíåå, ó áîëüíûõ ÎÀ, èìåþùèõ äîâîëüíî ñêóäíûé âûáîð - ïàðàöåòàìîë, ÖÎÃ2-èíãèáèòîðû èëè òðàìàë +/ïàðàöåòàìîë, õîíäðîïðîòåêòîðû âïîëíå ÷åñòíî çàíÿëè ñâîþ òåðàïåâòè÷åñêóþ íèøó. Âåäü ÷òî âàæíî äëÿ ïðàêòè÷åñêîãî âðà÷à? Èñïîëüçóÿ äàííûå ñîâðåìåííûõ è êà÷åñòâåííûõ èññëåäîâàíèé, ëå÷èòü êîíêðåòíîãî áîëüíîãî, äîáèâøèñü ìèíèìóìà ïîáî÷íûõ ýôôåêòîâ. Ïîýòîìó ÍÈÊÒÎ, íè â ÑØÀ, íè â Ðîññèè ÍÅ ÎÑÓÄÈÒ ìåíÿ èëè åùå êîãî-ëèáî çà íàçíà÷åíèå àðòðû èëè ñòðóêòóìà.

Öèòàòà:
Ñîîáùåíèå îò Hard
ïðîèçâîäÿòñÿ èç êîðîâüèõ õðÿùåé èëè êðåâåòî÷íûõ õèòèíîâ, ïðîäàþòñÿ äëÿ ïîòðåáëåíèÿ áîëüíûìè ñ àðòðèòàìè èëè ïðîñòî "îò âñåõ áîëåçíåé", ÿâëÿþòñÿ
À âàðôàðèí - âîîáùå êðûñèíûé ÿä, à êîòëåòû - øàðèêè èç òðóïîâ ìåðòâûõ æèâîòíûõ

Öèòàòà:
Ñîîáùåíèå îò Hard
(âíå ñâÿçè ñ òåì, ÷òî ïåðåïå÷àòûâàåòñÿ â Õàððèñîíå èç èçäàíèÿ â èçäàíèå íà ïðîòÿæåíèå äåñÿòêîâ ëåò)
Íó, ýòî Âû çðÿ òàê ïðî óâàæàåìîå ðóêîâîäñòâî ñóäèòå. Òåì íå ìåíåå, ñïåöèàëüíî äëÿ âàñ ÿ öèòèðîâàë èññëåäîâàíèÿ è ðóêîâîäñòâà 2006 è 2007 ãîäîâ (à êîå-÷òî - è Âû ñàìè)

Öèòàòà:
Ñîîáùåíèå îò Hard
(Ñì. "backgraund"; èç èñòîðèè
Ñïàñèáî, ÿ ëó÷øå ïîñìîòðþ ðóêîâîäñòâî, â êîòîðîì ïèøóò background

Öèòàòà:
Ñîîáùåíèå îò Hard
êîå-ãäå â Åâðîïå îíè ïîêà åùå îñòàþòñÿ òèïà ëåêàðñòâàìè...)
Äà, êîå-ãäå íà áÎëüøåé ÷àñòè çåìíîãî øàðà â íàèáîëåå öèâèëèçîâàííûõ ñòðàíàõ. Óäèâëÿþñü, êàê ìîæíî ðàçäóòü ñïîð èç íè÷åãî
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 03.02.2007, 22:32
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Åñòü ïðåòåíçèè ê äèçàéíó? Ê æóðíàëàì, èõ îïóáëèêîâàâøèì? Ê àìåðèêàíñêèì ðóêîâîäñòâàì ïî ÎÀ?
Ïðåòåíçèé íåò. Åñòü îäèí åäèíñòâåííûé âîïðîñ: íàçîâèòå êîíêðåòíûé õîíäðîïðîòåêòîð, ïåðå÷èñëåííûé â íàéäåííîì Âàìè ãàéäëàéíå èëè â òîì æå Õàððèñîíå, êîòîðûé åãî èçäàòåëÿìè îïðåäåëÿëñÿ áû ëåêàðñòâîì, à íå ÁÀÄîì.


PS:
Öèòàòà:
ÍÈÊÒÎ, íè â ÑØÀ, íè â Ðîññèè ÍÅ ÎÑÓÄÈÒ ìåíÿ èëè åùå êîãî-ëèáî çà íàçíà÷åíèå àðòðû èëè ñòðóêòóìà.
Îñóæäàòü äîêòîðà çà íàçíà÷åíèå áèîäîáàâîê íå ïðèíÿòî. Åäèíñòâåííî, â Ðîññèè Âû ìîæåòå íàçûâàòü ýòî "íàçíà÷åíèåì ëåêàðñòâ", à â ÑØÀ - ïðèäåòñÿ óòî÷íÿòü, ÷òî ðåêîìåíäóåòå "êóïèòü ñàïïëèìåíò (ÁÀÄ ïî-íàøåìó)".
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 04.02.2007, 14:12
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Ïðåòåíçèé íåò.
Îòëè÷íî, ïðåòåíçèé íåò, ýâèäåíñ - åñòü, êëèíè÷åñêèå ðåêîìåíäàöèè - ïðèñóòñòâóþò (åñëè çàáûëè, êàêèå èìåííî - ïðîöèòèðóþ ãàéä) - äëÿ ìåíÿ, êàê ïðàêòè÷åñêîãî âðà÷à, ïðèäåðæèâàþùåãîñÿ ïðèíöèïîâ ìåäèöèíû, îñíîâàííîé íà äîêàçàííîì, ýòîãî âïîëíå äîñòàòî÷íî

Öèòàòà:
Ñîîáùåíèå îò Hard
Åñòü îäèí åäèíñòâåííûé âîïðîñ: íàçîâèòå êîíêðåòíûé õîíäðîïðîòåêòîð, ïåðå÷èñëåííûé â íàéäåííîì Âàìè ãàéäëàéíå èëè â òîì æå Õàððèñîíå, êîòîðûé åãî èçäàòåëÿìè îïðåäåëÿëñÿ áû ëåêàðñòâîì, à íå ÁÀÄîì.
Îòâå÷ó íà íåãî ñðàçó ïîñëå òîãî, êàê Âû ìíå íàéäåòå â ýòîì æå ãàéäëàéíå ëþáîé áðýíä íýéì ëþáîãî äðóãîãî ëåêàðñòâåííîãî ñðåäñòâà . Íàïîìíþ, ÷òî áðýíäîâûå èìåíà íå ïðèíÿòî óêàçûâàòü â ïðèëè÷íûõ ðóêîâîäñòâàõ. Óêàçàíû êîíêðåòíûå âåùåñòâà - ãëþêîçàìèí è õîíäðîèòèí. À óæ ãäå ìíå âçÿòü ëåêàðñòâà:

Öèòàòà:

Molécule(s) Chondroïtine sulfate


Classe thérapeutique Antiarthrosique



Laboratoire(s) Pierre Fabre




Indications STRUCTUM est utilisé dans le traitement des manifestations de l'arthrose.

Informations pratiques Délivré sans ordonnance.


Mode d'action Cette molécule inhibe l'élastase, enzyme responsable de la dégradation du cartilage, et favorise la synthése de cartilage.



Effets secondaires Des manifestations cutanées allergiques, des nausées ou des vomissements ont été observés avec STRUCTUM.


Contre-indications /
Précautions d'emploi STRUCTUM est contre-indiqué en cas d'allergie à l'un des constituants et chez l'enfant de moins de 16 ans.

En cas de grossesse ou d'allaitement, ne prenez STRUCTUM que sur avis médical.


Interactions
médicamenteuses Pas d'interaction répertoriée.


Surdosage En cas de doute, contactez rapidement votre médecin traitant ou le centre antipoison le plus proche.


Öèòàòà:
Ñîîáùåíèå îò Hard

PS: Îñóæäàòü äîêòîðà çà íàçíà÷åíèå áèîäîáàâîê íå ïðèíÿòî. Åäèíñòâåííî, â Ðîññèè Âû ìîæåòå íàçûâàòü ýòî "íàçíà÷åíèåì ëåêàðñòâ", à â ÑØÀ - ïðèäåòñÿ óòî÷íÿòü, ÷òî ðåêîìåíäóåòå "êóïèòü ñàïïëèìåíò (ÁÀÄ ïî-íàøåìó)".
À ÿ íå æèâó â ÑØÀ è ôàíòàçèè FDA ìíå íå óêàç . Ìîå äåëî - ëå÷èòü êîíêðåòíûõ ëþäåé, èñïîâåäóÿ ïðèíöèïû EBM.  Ðîññèè è Åâðîïå åñòü ñîäåðæàùèå ãëþêîçàìèí +/- õîíäðîèòèí ëåêàðñòâåííûå ñðåäñòâà è ìîÿ ñîâåñòü ÷èñòà

Êîììåíòàðèè ê ñîîáùåíèþ:
riltsov îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 05.02.2007, 02:47
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Äëÿ êîãî ÿ öèòèðîâàë:

See Related Guideline from CURRENT Practice Guidelines in Primary Care 2006
Äåéñòâèòåëüíî, íåóæåëè äëÿ òåõ, êîìó

Öèòàòà:
ôàíòàçèè FDA ìíå íå óêàç
Ïîçèöèÿ íå íîâàÿ è íà ôîðóìå âñòðå÷àþùàÿñÿ ïåðèîäè÷åñêè (âñåì èçâåñòíî, ñðåäè ïðèâåðæåíöåâ ÷åãî).

Öèòàòà:
 Ðîññèè è Åâðîïå åñòü ñîäåðæàùèå ãëþêîçàìèí +/- õîíäðîèòèí ëåêàðñòâåííûå ñðåäñòâà è ìîÿ ñîâåñòü ÷èñòà
Íèêòî íà Âàøó ñîâåñòü íå ïîñÿãàåò - ýòî Âàøå ëè÷íîå äåëî. Íà íåé íå îòðàçèòñÿ, åñëè Âû íàéäåòå åùå ìàññó òèïà "ëåêàðñòâåííûõ â Ðîññèè è Åâðîïå ñðåäñòâ", íàïðèìåð, íîîòðîïîâ è âèòàìèíîâ.

Öèòàòà:
Îòëè÷íî, ïðåòåíçèé íåò, ýâèäåíñ - åñòü, êëèíè÷åñêèå ðåêîìåíäàöèè - ïðèñóòñòâóþò (åñëè çàáûëè, êàêèå èìåííî - ïðîöèòèðóþ ãàéä)
Çà÷åì æå öèòèðîâàòü òî, ÷òî äëÿ Âàñ íå óêàç? Ëó÷øå ïåðå÷èòàéòå ñòàòüè, ê êîòîðûì ó íàñ ñ Âàìè "íåò ïðåòåíçèé". Òàì ÿñíî ñêàçàíî, ÷òî[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].

Ýòî è åñòü òîò óðîâåíü èññëåäîâàíèé, êîòîðûé ïîçâîëÿåò âûïóñêàòü ñîîòâåòñòâóþùèå ïðåïàðàòû â âèäå ÁÀÄîâ è íèêàê íå äîïóñêàåò ñ÷èòàòü èõ ëåêàðñòâàìè (åñëè, êîíå÷íî, íå ïðîèçâîäèòü èõ â Ðîññèè è ðÿäå åâðîïåéñêèõ ñòðàí ñ çà÷àòî÷íî äîêàçàòåëüíûì çàêîíîäàòåëüñòâîì â ôàðì ñôåðå).
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 05.02.2007, 17:57
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Çà÷åì æå öèòèðîâàòü òî, ÷òî äëÿ Âàñ íå óêàç? Ëó÷øå ïåðå÷èòàéòå ñòàòüè, ê êîòîðûì ó íàñ ñ Âàìè "íåò ïðåòåíçèé". Òàì ÿñíî ñêàçàíî, ÷òî[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].
Íó à ïðè ÷åì òóò FDA, ìîå äåëî - ýâèäåíñ. Îáðàòèòå âíèìàíèå, ÷òî ýòî ÿ, äèêèé ðóñè÷, öèòèðóþ Âàì ñîâðåìåííûå ãàéäû, ðóêîâîäñòâà è ò.ä., à Âû ìíå ïðåäëàãàåòå îñèëèâàòü "àíòèøàðëàòàíñêèå" ñòàòüè, àâòîðû êîòîðûõ ñëîâî background ïðàâèëüíî íàïèñàòü íå ìîãóò (ñòàòüþ â nejm'å íå èìåþ ââèäó)

Öèòàòà:
Ñîîáùåíèå îò Hard
è ðÿäå åâðîïåéñêèõ ñòðàí ñ çà÷àòî÷íî äîêàçàòåëüíûì çàêîíîäàòåëüñòâîì â ôàðì ñôåðå).
Ýòî ïðî Ôðàíöèþ ÷òî ëè? Æåñòêî . À ýòà öèòàòà Âàì êàê ïîíðàâèëàñü èç äåéñòâóþùåãî ãàéäà (): "It is reasonable to recommend a 60-day trial of the combination of glucosamine and chondroitin sulfate"? "Ýòî Âàì íå ïðèâîç, ýòî þíàéòåä ñòåéòñ îô-òàêè àìåðèêà (ñ)"

Âñå-òàêè ïîëó÷àåòñÿ, ÷òî äàííûå âåùåñòâà - è åñòü ïðèìåð ÁÀÄîâ, êîòîðûå äîêàçàëè ñâîé òåðàïåâòè÷åñêèé ýôôåêò. Ê ñîæàëåíèþ, Âû îøèáàëèñü, êîãäà ïèñàëè, ÷òî ê íèì 7 ëåò êàê óæå ïîòåðÿëè èíòåðåñ , êàê è îøèáàëèñü â òîì, ÷òî îíè "åùå êîå-ãäå-òî-êàê-òî" íàçûâàþòñÿ ëåêàðñòâàìè .
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 06.02.2007, 04:21
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Âñå-òàêè ïîëó÷àåòñÿ, ÷òî äàííûå âåùåñòâà - è åñòü ïðèìåð ÁÀÄîâ, êîòîðûå äîêàçàëè ñâîé òåðàïåâòè÷åñêèé ýôôåêò.
Ò.å, Âû âñå-òàêè ñîãëàñíû, ÷òî äàííûå âåùåñòâà îôèöèàëüíî ñ÷èòàþòñÿ ÁÀÄàìè? À òî, êàê-òî íåëîãè÷íî ïîëó÷àåòñÿ: íà êíèæêè ññûëàåòåñü - öèòèðóåòå, à ïðî îôèöèàëüíóþ ñèòóàöèþ íà òåððèòîðèè, ãäå êíèæêè ïå÷àòàëèñü, ò.å. ïðî âûâîäû è ðåçóëüòàòû - óïîìÿíóòü çàáûâàåòå.
Öèòàòà:
Âû îøèáàëèñü, êîãäà ïèñàëè, ÷òî ê íèì 7 ëåò êàê óæå ïîòåðÿëè èíòåðåñ
ß æå íå ãîâîðèë, ÷òî âñå ïîòåðÿëè èíòåðåñ - ÁÀÄîòîðãîâöû î÷åíü äàæå èíòåðåñóþòñÿ.

Öèòàòà:
Ýòî ïðî Ôðàíöèþ ÷òî ëè? Æåñòêî
Íè÷åãî, Ôðàíöèÿ ñ åå ìîùíîé ãîìåîïàòèåé, âèòàìèíîòåðàïèåé è íîîòðîïîëå÷åíèåì è íå òàêîå ÷èòàåò.
Öèòàòà:
ìîå äåëî - ýâèäåíñ.
Åñëè Âû ïðî ôðàíöóçñêèé âàðèàíò ýâèäåíñà, òî ìîæåòå ê õîíäðîïðîòåêòîðàì äîáàâèòü åùå è òàíàêàí, è ìàãíå-Â6, è åùå ìíîãî ÷åãî, "äîêàçàííîãî âî Ôðàíöèè" è ëþáèìîãî íà ïîñòñîâåòñêîì ïðîñòðàíñòâå.

Êîììåíòàðèè ê ñîîáùåíèþ:
yananshs îäîáðèë(à):
Mikhail îäîáðèë(à): Íàñ÷åò "ôðàíöèÿ - íå àðãóìåíò" ñîãëàñåí, íî â öåëîì - íå î÷åíü . Âñå òàêè âîïðîñ äîñòàòî÷íî ñïîðíûé è ïîêà äàëåêî íå îäíîçíà÷íûé.
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 06.02.2007, 18:31
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Hard
Ò.å, Âû âñå-òàêè ñîãëàñíû, ÷òî äàííûå âåùåñòâà îôèöèàëüíî ñ÷èòàþòñÿ ÁÀÄàìè? À òî, êàê-òî íåëîãè÷íî ïîëó÷àåòñÿ: íà êíèæêè ññûëàåòåñü - öèòèðóåòå, à ïðî îôèöèàëüíóþ ñèòóàöèþ íà òåððèòîðèè, ãäå êíèæêè ïå÷àòàëèñü, ò.å. ïðî âûâîäû è ðåçóëüòàòû - óïîìÿíóòü çàáûâàåòå.
À òåïåðü íàïîìíþ, ñ ÷åãî íà÷èíàëàñü òåìà . Òåìà íà÷èíàëàñü ñ òîãî, ÷òîÿ ïîäâåðã êðèòèêå âîò ýòî ñóæäåíèå: "PS: Òåìà î âûòÿæêàõ-õîíäðîïðîòåêòîðàõ óæå íå ðàç îáñóæäàëàñü. Ðåçþìå äîëæíî çâó÷àòü â òîì òîíå, ÷òî ýòè òîâàðû ÿâëÿþòñÿ ëåêàðñòâàìè ïî ôîðìå (êîå-ãäå åùå ïîðîé ), íî ÁÀÄàìè ïî ñîäåðæàíèþ".

ß ïðèâåë íåîáõîäèìûå äîêàçàòåëüñòâà, ÷òîáû äàòü ïîíÿòü - ýòî ÁÀÄàìè îíè ñ÷èòàþòñÿ åùå êîå-ãäå-òî-ïîðîé (ÿ íå íàñòîëüêî âåëèêèé ôàíàò ÑØÀ, ÷òîáû ñ÷èòàòü èõ áÎëüøåé ÷àñòüþ ìèðà ), à âî âñåì îñòàëüíîì ìèðå ýòî - ëåêàðñòâà. ×òî ñîâåðøåííî ÍÅ ÈÑÊËÞ×ÀÅÒ íåîáõîäèìîñòü ïîñòìàðêåòèíãîâûõ èññëåäîâàíèé.

Äåéñòâèòåëüíî, ýâèäåíñ, êîòîðûé èãðàåò íà ðóêó õîíäðîïðîòåêòîðàì, ÿ áðàë èç àìåðèêàíñêèõ ðóêîâîäñòâ ïîòîìó, ÷òî îíè áîëåå óáåäèòåëüíû, à èõ àâòîðû - òðàäèöèîííî íàèáîëåå îñòîðîæíû â ñâîèõ âûâîäàõ è ñóæäåíèÿõ, ÷òî ìíå è íðàâèòñÿ. Åñëè íóæíî - ìîãó ïðèâåñòè ïóáëèêàöèè è äðóãèõ ñòðàí

Êîíå÷íî, óäèâèòåëüíî, ÷òî, íåñìîòðÿ íà ìíîãî÷èñëåííûå óïîìèíàíèÿ â ðàçëè÷íûõ ðóêîâîäñòâàõ â ðàçäåëå "ËÅ×ÅÍÈÅ" èõ åùå íå ïðè÷èñëèëè ê ëåêàðñòâàì, íî ÷òî æ ïîäåëàòü - âðåìÿ ïîêàæåò.

Öèòàòà:
Ñîîáùåíèå îò Hard
Âû ïðî ôðàíöóçñêèé âàðèàíò ýâèäåíñà, òî ìîæåòå ê õîíäðîïðîòåêòîðàì äîáàâèòü åùå è òàíàêàí, è ìàãíå-Â6, è åùå ìíîãî ÷åãî, "äîêàçàííîãî âî Ôðàíöèè" è ëþáèìîãî íà ïîñòñîâåòñêîì ïðîñòðàíñòâå.
Ýòî âîîáùå íå âàðèàíò ýâèäåíñà, ýòî àííîòàöèÿ ê ïðåïàðàòó, âûïóñêàåìîãî Ïüåð Ôàáð Ïðîñòî çàòåì, ÷òîáû ïîêàçàòü ëåêàðñòâåííîå ïðîèñõîæäåíèå
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 11.02.2007, 22:00
dr.gala dr.gala âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ã.Ìèðíûé
Ñîîáùåíèé: 12
dr.gala *
Âíèìàòåëüíî ÷èòàëà äèñêóññèþ...Âîò òàê äîëãî, íåêðàñèâî è ìó÷èòåëüíî ðîæäàåòñÿ èñòèíà !
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 17.02.2007, 19:26
Mystical Mystical âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 11.02.2007
Ãîðîä: Íàðî-Ôîìèíñê
Ñîîáùåíèé: 15
Mystical *
æàëêî íå âëàäåþ ëàòèíñêèì , íàâåðíî ìíîãî óïóñòèë
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:21.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.